Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Supreme Court Decisions | 18 | 2024 | 135 | 4.980 |
Why?
|
School Admission Criteria | 3 | 2024 | 106 | 2.270 |
Why?
|
Periodicals as Topic | 13 | 2024 | 1465 | 1.870 |
Why?
|
Drug Industry | 10 | 2018 | 791 | 1.870 |
Why?
|
Prescription Drugs | 5 | 2022 | 635 | 1.760 |
Why?
|
Patents as Topic | 3 | 2020 | 111 | 1.600 |
Why?
|
Liability, Legal | 5 | 2018 | 209 | 1.540 |
Why?
|
Civil Rights | 6 | 2024 | 130 | 1.400 |
Why?
|
Drug Labeling | 3 | 2024 | 251 | 1.340 |
Why?
|
Fraud | 2 | 2020 | 66 | 1.310 |
Why?
|
Government Regulation | 9 | 2018 | 525 | 1.280 |
Why?
|
Politics | 5 | 2024 | 822 | 1.270 |
Why?
|
Patient Protection and Affordable Care Act | 7 | 2020 | 1188 | 1.240 |
Why?
|
United States Food and Drug Administration | 13 | 2024 | 1672 | 1.240 |
Why?
|
Cultural Diversity | 4 | 2023 | 373 | 1.220 |
Why?
|
Publishing | 10 | 2024 | 837 | 1.190 |
Why?
|
Editorial Policies | 6 | 2024 | 458 | 1.160 |
Why?
|
Preventive Health Services | 2 | 2023 | 570 | 1.110 |
Why?
|
Physicians | 6 | 2023 | 4593 | 1.090 |
Why?
|
Eicosapentaenoic Acid | 2 | 2021 | 565 | 1.090 |
Why?
|
Fatty Acids, Omega-3 | 3 | 2021 | 1399 | 1.030 |
Why?
|
Drug Approval | 6 | 2024 | 820 | 1.000 |
Why?
|
Device Approval | 5 | 2011 | 164 | 0.990 |
Why?
|
Tobacco Industry | 2 | 2021 | 139 | 0.980 |
Why?
|
Health Care Reform | 4 | 2020 | 1256 | 0.950 |
Why?
|
Firearms | 4 | 2017 | 630 | 0.950 |
Why?
|
United States Public Health Service | 2 | 2014 | 31 | 0.930 |
Why?
|
Pharmacies | 3 | 2018 | 171 | 0.930 |
Why?
|
Chelation Therapy | 1 | 2024 | 77 | 0.920 |
Why?
|
Edetic Acid | 1 | 2024 | 277 | 0.900 |
Why?
|
United States | 53 | 2024 | 72971 | 0.860 |
Why?
|
Medicine, Chinese Traditional | 1 | 2023 | 75 | 0.850 |
Why?
|
Alendronate | 1 | 2024 | 174 | 0.840 |
Why?
|
Chelating Agents | 1 | 2024 | 384 | 0.830 |
Why?
|
Drugs, Generic | 3 | 2018 | 457 | 0.830 |
Why?
|
Schools, Medical | 2 | 2024 | 883 | 0.820 |
Why?
|
American Hospital Association | 1 | 2022 | 26 | 0.800 |
Why?
|
Legislation, Drug | 5 | 2018 | 216 | 0.790 |
Why?
|
Disclosure | 3 | 2024 | 755 | 0.780 |
Why?
|
Health Benefit Plans, Employee | 3 | 2020 | 332 | 0.750 |
Why?
|
Drug Costs | 4 | 2022 | 1196 | 0.750 |
Why?
|
Digitalis Glycosides | 1 | 2020 | 47 | 0.740 |
Why?
|
Women's Health Services | 1 | 2020 | 87 | 0.690 |
Why?
|
Family Planning Services | 1 | 2023 | 279 | 0.680 |
Why?
|
Charities | 1 | 2019 | 35 | 0.660 |
Why?
|
Contraceptive Agents | 1 | 2020 | 147 | 0.640 |
Why?
|
Congresses as Topic | 1 | 2024 | 812 | 0.640 |
Why?
|
Cardiovascular Diseases | 10 | 2021 | 15645 | 0.630 |
Why?
|
Duty to Warn | 1 | 2018 | 30 | 0.620 |
Why?
|
Secondary Prevention | 2 | 2024 | 1472 | 0.620 |
Why?
|
Tetrabenazine | 1 | 2018 | 21 | 0.610 |
Why?
|
Interdisciplinary Communication | 1 | 2024 | 935 | 0.600 |
Why?
|
Joint Commission on Accreditation of Healthcare Organizations | 1 | 2018 | 91 | 0.600 |
Why?
|
Renin | 2 | 2020 | 647 | 0.590 |
Why?
|
Judicial Role | 1 | 2018 | 38 | 0.590 |
Why?
|
Causality | 1 | 2024 | 1253 | 0.580 |
Why?
|
Heart-Assist Devices | 2 | 2019 | 1287 | 0.580 |
Why?
|
Abortion, Induced | 1 | 2023 | 471 | 0.560 |
Why?
|
Public Health | 5 | 2024 | 2681 | 0.560 |
Why?
|
Access to Information | 4 | 2014 | 317 | 0.550 |
Why?
|
Universities | 3 | 2022 | 1004 | 0.550 |
Why?
|
Azetidines | 2 | 2008 | 151 | 0.550 |
Why?
|
Bone Density Conservation Agents | 1 | 2024 | 797 | 0.540 |
Why?
|
Valine | 1 | 2018 | 410 | 0.540 |
Why?
|
Renal Dialysis | 2 | 2022 | 1790 | 0.540 |
Why?
|
Reproductive Rights | 2 | 2014 | 31 | 0.530 |
Why?
|
Myocardial Infarction | 9 | 2024 | 11513 | 0.510 |
Why?
|
Heart Valve Diseases | 3 | 2021 | 1029 | 0.510 |
Why?
|
Hip Fractures | 1 | 2024 | 997 | 0.510 |
Why?
|
Databases as Topic | 2 | 2015 | 472 | 0.500 |
Why?
|
Private Sector | 2 | 2016 | 397 | 0.500 |
Why?
|
Fentanyl | 1 | 2019 | 451 | 0.500 |
Why?
|
Myositis | 1 | 2018 | 268 | 0.500 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2018 | 3249 | 0.490 |
Why?
|
Confidentiality | 2 | 2011 | 607 | 0.490 |
Why?
|
Aldosterone | 2 | 2020 | 881 | 0.490 |
Why?
|
Insurance Claim Reporting | 1 | 2015 | 166 | 0.490 |
Why?
|
Mandatory Programs | 2 | 2014 | 86 | 0.480 |
Why?
|
Humans | 107 | 2024 | 767040 | 0.480 |
Why?
|
Biomedical Research | 7 | 2021 | 3464 | 0.480 |
Why?
|
Appetite Depressants | 2 | 2010 | 108 | 0.480 |
Why?
|
Industry | 2 | 2014 | 362 | 0.460 |
Why?
|
State Government | 7 | 2018 | 388 | 0.450 |
Why?
|
Patient Care Management | 1 | 2017 | 302 | 0.450 |
Why?
|
Therapeutics | 1 | 2014 | 113 | 0.450 |
Why?
|
Muscular Diseases | 1 | 2018 | 552 | 0.450 |
Why?
|
Public Policy | 3 | 2023 | 551 | 0.450 |
Why?
|
Hypotension | 1 | 2019 | 888 | 0.440 |
Why?
|
Peer Review, Research | 4 | 2008 | 343 | 0.440 |
Why?
|
Jurisprudence | 2 | 2017 | 109 | 0.430 |
Why?
|
Administrative Personnel | 1 | 2014 | 185 | 0.430 |
Why?
|
Primary Prevention | 2 | 2018 | 1188 | 0.420 |
Why?
|
Opioid-Related Disorders | 2 | 2018 | 2188 | 0.420 |
Why?
|
Clinical Trials as Topic | 5 | 2024 | 8048 | 0.410 |
Why?
|
Religion and Medicine | 1 | 2014 | 161 | 0.410 |
Why?
|
Atrial Fibrillation | 2 | 2021 | 5180 | 0.390 |
Why?
|
Fractures, Bone | 1 | 2024 | 2062 | 0.390 |
Why?
|
Contraceptives, Oral | 1 | 2014 | 560 | 0.380 |
Why?
|
Federal Government | 1 | 2013 | 266 | 0.380 |
Why?
|
Authorship | 3 | 2003 | 289 | 0.370 |
Why?
|
Anticholesteremic Agents | 2 | 2008 | 969 | 0.360 |
Why?
|
Equipment Safety | 2 | 2009 | 250 | 0.360 |
Why?
|
Scopolamine Derivatives | 1 | 2010 | 23 | 0.360 |
Why?
|
Patient Rights | 2 | 2008 | 126 | 0.360 |
Why?
|
Data Interpretation, Statistical | 1 | 2020 | 2698 | 0.350 |
Why?
|
Cyclobutanes | 1 | 2010 | 57 | 0.350 |
Why?
|
Heart Failure | 6 | 2019 | 11877 | 0.350 |
Why?
|
Hypertension | 2 | 2020 | 8615 | 0.330 |
Why?
|
Medicare | 3 | 2022 | 6813 | 0.320 |
Why?
|
Simvastatin | 2 | 2008 | 345 | 0.310 |
Why?
|
Health Services Accessibility | 6 | 2020 | 5519 | 0.310 |
Why?
|
Insurance Coverage | 4 | 2020 | 1945 | 0.310 |
Why?
|
Legislation, Medical | 1 | 2009 | 99 | 0.310 |
Why?
|
Drug and Narcotic Control | 1 | 2009 | 145 | 0.300 |
Why?
|
Dietary Supplements | 2 | 2021 | 3446 | 0.290 |
Why?
|
Capital Punishment | 1 | 2008 | 30 | 0.290 |
Why?
|
Heart Diseases | 1 | 2021 | 2817 | 0.290 |
Why?
|
Physician-Patient Relations | 3 | 2017 | 3266 | 0.290 |
Why?
|
Analgesics, Opioid | 3 | 2019 | 3837 | 0.290 |
Why?
|
Abortion, Legal | 1 | 2008 | 121 | 0.280 |
Why?
|
Medicaid | 3 | 2019 | 2836 | 0.280 |
Why?
|
Insurance, Health | 4 | 2019 | 2519 | 0.270 |
Why?
|
Bronchodilator Agents | 1 | 2010 | 513 | 0.270 |
Why?
|
Data Collection | 1 | 2016 | 3321 | 0.270 |
Why?
|
Blood Pressure | 5 | 2020 | 8531 | 0.270 |
Why?
|
Cholesterol, LDL | 3 | 2014 | 2392 | 0.270 |
Why?
|
Antitrust Laws | 2 | 2018 | 8 | 0.270 |
Why?
|
Prosthesis Failure | 1 | 2011 | 1208 | 0.260 |
Why?
|
Acute Coronary Syndrome | 1 | 2019 | 2193 | 0.260 |
Why?
|
Product Labeling | 2 | 2021 | 75 | 0.250 |
Why?
|
Health Care Costs | 2 | 2016 | 3239 | 0.250 |
Why?
|
Blood Pressure Determination | 2 | 2020 | 646 | 0.250 |
Why?
|
Naproxen | 1 | 2006 | 101 | 0.250 |
Why?
|
State Health Plans | 1 | 2007 | 220 | 0.250 |
Why?
|
Conflict of Interest | 4 | 2016 | 556 | 0.250 |
Why?
|
Leukoplakia, Oral | 1 | 2006 | 79 | 0.250 |
Why?
|
Delivery of Health Care | 3 | 2024 | 5363 | 0.250 |
Why?
|
Hip Prosthesis | 1 | 2011 | 924 | 0.240 |
Why?
|
Comparative Effectiveness Research | 1 | 2010 | 713 | 0.240 |
Why?
|
Violence | 2 | 2008 | 931 | 0.240 |
Why?
|
Copyright | 1 | 2004 | 13 | 0.240 |
Why?
|
Medicine | 2 | 2023 | 944 | 0.240 |
Why?
|
Information Dissemination | 2 | 2023 | 1142 | 0.230 |
Why?
|
Health Expenditures | 1 | 2017 | 2390 | 0.230 |
Why?
|
Drug Prescriptions | 2 | 2011 | 1664 | 0.230 |
Why?
|
Thiazolidinediones | 1 | 2007 | 460 | 0.230 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 3232 | 0.220 |
Why?
|
Lactones | 1 | 2006 | 315 | 0.220 |
Why?
|
Coronary Disease | 7 | 2007 | 5914 | 0.220 |
Why?
|
Retraction of Publication as Topic | 1 | 2003 | 10 | 0.210 |
Why?
|
Sulfones | 1 | 2006 | 447 | 0.210 |
Why?
|
Cadmium | 1 | 2024 | 218 | 0.210 |
Why?
|
Taxes | 3 | 2012 | 220 | 0.210 |
Why?
|
Hyperlipoproteinemia Type II | 1 | 2008 | 396 | 0.210 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2006 | 497 | 0.210 |
Why?
|
Heart Arrest | 3 | 2017 | 1516 | 0.210 |
Why?
|
Stents | 2 | 2007 | 3193 | 0.210 |
Why?
|
Hypocalcemia | 1 | 2024 | 205 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3112 | 0.200 |
Why?
|
Ethics, Medical | 1 | 2008 | 785 | 0.200 |
Why?
|
Fractures, Spontaneous | 1 | 2024 | 232 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3234 | 0.200 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2024 | 10393 | 0.200 |
Why?
|
Informed Consent | 1 | 2008 | 1010 | 0.200 |
Why?
|
Smoking | 2 | 2009 | 9081 | 0.190 |
Why?
|
Ventricular Premature Complexes | 1 | 2003 | 112 | 0.190 |
Why?
|
Vasodilator Agents | 2 | 2019 | 988 | 0.190 |
Why?
|
Minority Groups | 2 | 2023 | 1214 | 0.190 |
Why?
|
Heart Transplantation | 2 | 2008 | 3305 | 0.190 |
Why?
|
Legislation as Topic | 1 | 2021 | 76 | 0.190 |
Why?
|
Lipid Regulating Agents | 1 | 2021 | 21 | 0.190 |
Why?
|
Bisoprolol | 1 | 2020 | 9 | 0.190 |
Why?
|
Hypoxia, Brain | 1 | 2002 | 139 | 0.190 |
Why?
|
Corn Oil | 1 | 2020 | 29 | 0.180 |
Why?
|
Health | 1 | 2024 | 398 | 0.180 |
Why?
|
Physician's Role | 1 | 2008 | 923 | 0.180 |
Why?
|
Atherosclerosis | 1 | 2017 | 3418 | 0.180 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2004 | 793 | 0.180 |
Why?
|
Mouth Neoplasms | 1 | 2006 | 597 | 0.180 |
Why?
|
Maine | 1 | 2020 | 146 | 0.180 |
Why?
|
Bone Remodeling | 1 | 2024 | 582 | 0.180 |
Why?
|
Pandemics | 1 | 2020 | 8736 | 0.170 |
Why?
|
Tissue and Organ Procurement | 1 | 2008 | 987 | 0.170 |
Why?
|
Physician Self-Referral | 1 | 2019 | 16 | 0.170 |
Why?
|
Angiotensins | 1 | 2020 | 140 | 0.170 |
Why?
|
Digoxin | 1 | 2020 | 246 | 0.170 |
Why?
|
Infusions, Intravenous | 1 | 2024 | 2227 | 0.170 |
Why?
|
Transplantation Chimera | 1 | 2002 | 594 | 0.160 |
Why?
|
Artificial Intelligence | 2 | 2024 | 2666 | 0.160 |
Why?
|
Weaning | 1 | 2019 | 102 | 0.160 |
Why?
|
Commerce | 2 | 2020 | 614 | 0.160 |
Why?
|
Lead | 1 | 2024 | 882 | 0.150 |
Why?
|
Tissue Donors | 1 | 2008 | 2387 | 0.150 |
Why?
|
Denmark | 1 | 2021 | 776 | 0.150 |
Why?
|
History, 21st Century | 2 | 2014 | 1574 | 0.150 |
Why?
|
Phentermine | 1 | 1997 | 31 | 0.140 |
Why?
|
Fenfluramine | 1 | 1997 | 58 | 0.140 |
Why?
|
Physical Exertion | 2 | 1993 | 667 | 0.140 |
Why?
|
Internet | 2 | 2009 | 3114 | 0.140 |
Why?
|
Rehabilitation Centers | 1 | 2019 | 249 | 0.140 |
Why?
|
Ventricular Fibrillation | 2 | 1998 | 538 | 0.140 |
Why?
|
Prescriptions | 1 | 2020 | 388 | 0.140 |
Why?
|
Gastrointestinal Diseases | 1 | 2006 | 1205 | 0.140 |
Why?
|
Costs and Cost Analysis | 1 | 2022 | 1666 | 0.140 |
Why?
|
Hypercholesterolemia | 2 | 2014 | 1144 | 0.140 |
Why?
|
Hypothermia, Induced | 1 | 2002 | 754 | 0.130 |
Why?
|
Intestinal Perforation | 1 | 2018 | 254 | 0.130 |
Why?
|
Dissent and Disputes | 1 | 2017 | 150 | 0.130 |
Why?
|
Clinical Coding | 1 | 2017 | 187 | 0.130 |
Why?
|
Economic Competition | 1 | 2018 | 223 | 0.130 |
Why?
|
Florida | 1 | 2017 | 417 | 0.130 |
Why?
|
Prosthesis Design | 3 | 2011 | 2120 | 0.130 |
Why?
|
Injections | 1 | 2019 | 839 | 0.130 |
Why?
|
Aortic Valve Stenosis | 1 | 2008 | 2021 | 0.130 |
Why?
|
Advance Directives | 1 | 2017 | 249 | 0.130 |
Why?
|
Vasodilation | 1 | 2019 | 968 | 0.120 |
Why?
|
Thoracic Injuries | 1 | 1998 | 288 | 0.120 |
Why?
|
Exercise Test | 2 | 2003 | 2188 | 0.120 |
Why?
|
Sirolimus | 1 | 2002 | 1539 | 0.120 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.120 |
Why?
|
Drug Therapy, Combination | 3 | 2010 | 6310 | 0.120 |
Why?
|
Australia | 1 | 2018 | 1263 | 0.120 |
Why?
|
Hypoglycemic Agents | 1 | 2007 | 3108 | 0.120 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 1515 | 0.110 |
Why?
|
Myocardium | 4 | 2002 | 4765 | 0.110 |
Why?
|
Practice Guidelines as Topic | 3 | 2018 | 7435 | 0.110 |
Why?
|
Exercise | 4 | 2003 | 5954 | 0.110 |
Why?
|
History, 20th Century | 2 | 2014 | 2765 | 0.110 |
Why?
|
Electrocardiography | 4 | 2023 | 6409 | 0.110 |
Why?
|
Patient Access to Records | 1 | 2014 | 120 | 0.110 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2020 | 1065 | 0.110 |
Why?
|
Research Support as Topic | 3 | 2008 | 697 | 0.110 |
Why?
|
Heart Rate | 5 | 2020 | 4209 | 0.110 |
Why?
|
Attitude of Health Personnel | 3 | 2023 | 3928 | 0.110 |
Why?
|
Patient-Centered Care | 1 | 2023 | 1444 | 0.110 |
Why?
|
Organizations | 1 | 2014 | 172 | 0.100 |
Why?
|
Standard of Care | 1 | 2017 | 569 | 0.100 |
Why?
|
Obesity | 2 | 2010 | 13085 | 0.100 |
Why?
|
Regeneration | 1 | 2002 | 1523 | 0.100 |
Why?
|
Security Measures | 2 | 2003 | 83 | 0.100 |
Why?
|
Nitroglycerin | 2 | 1984 | 332 | 0.100 |
Why?
|
Bioterrorism | 2 | 2003 | 144 | 0.100 |
Why?
|
Appendicitis | 1 | 2018 | 679 | 0.100 |
Why?
|
Education, Medical | 1 | 2024 | 1746 | 0.100 |
Why?
|
Wounds, Nonpenetrating | 1 | 1998 | 807 | 0.100 |
Why?
|
Texas | 1 | 2013 | 410 | 0.100 |
Why?
|
Drug Compounding | 1 | 2012 | 236 | 0.090 |
Why?
|
Risk | 3 | 2017 | 9606 | 0.090 |
Why?
|
Aortic Valve | 2 | 2021 | 1968 | 0.090 |
Why?
|
Asthma | 1 | 2010 | 6268 | 0.090 |
Why?
|
Vermont | 1 | 2011 | 80 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2003 | 1946 | 0.090 |
Why?
|
Calcium | 1 | 2024 | 5792 | 0.090 |
Why?
|
Beclomethasone | 1 | 2010 | 38 | 0.090 |
Why?
|
Chest Pain | 1 | 2018 | 1101 | 0.090 |
Why?
|
Myosins | 1 | 1992 | 406 | 0.090 |
Why?
|
Stem Cell Transplantation | 1 | 2019 | 1596 | 0.090 |
Why?
|
Arthritis, Rheumatoid | 1 | 2006 | 3778 | 0.090 |
Why?
|
Risk Factors | 5 | 2021 | 74886 | 0.090 |
Why?
|
Death, Sudden, Cardiac | 1 | 1998 | 1567 | 0.080 |
Why?
|
Heart | 3 | 2002 | 4429 | 0.080 |
Why?
|
Communication | 1 | 2024 | 3904 | 0.080 |
Why?
|
Cholinergic Antagonists | 1 | 2010 | 166 | 0.080 |
Why?
|
Health Personnel | 1 | 2023 | 3387 | 0.080 |
Why?
|
Cultural Competency | 1 | 2013 | 303 | 0.080 |
Why?
|
Albuterol | 1 | 2010 | 211 | 0.080 |
Why?
|
Immunosuppressive Agents | 1 | 2002 | 4210 | 0.080 |
Why?
|
South Dakota | 1 | 2008 | 32 | 0.080 |
Why?
|
Marketing | 1 | 2011 | 225 | 0.080 |
Why?
|
Women's Health | 1 | 2018 | 2082 | 0.080 |
Why?
|
Cardiotonic Agents | 1 | 1991 | 540 | 0.080 |
Why?
|
Eligibility Determination | 1 | 2012 | 421 | 0.080 |
Why?
|
District of Columbia | 1 | 2008 | 159 | 0.070 |
Why?
|
Wounds, Gunshot | 1 | 2014 | 586 | 0.070 |
Why?
|
Tunica Media | 1 | 2008 | 107 | 0.070 |
Why?
|
Athletic Injuries | 1 | 1998 | 1245 | 0.070 |
Why?
|
Quality of Health Care | 2 | 2023 | 4306 | 0.070 |
Why?
|
Local Government | 1 | 2008 | 83 | 0.070 |
Why?
|
Kidney | 2 | 2022 | 7063 | 0.070 |
Why?
|
Administration, Inhalation | 1 | 2010 | 1154 | 0.070 |
Why?
|
Mortality | 2 | 2003 | 2909 | 0.070 |
Why?
|
Vitamin D | 1 | 2021 | 3312 | 0.070 |
Why?
|
Female | 18 | 2023 | 396660 | 0.070 |
Why?
|
Hypertension, Pulmonary | 1 | 1997 | 1604 | 0.070 |
Why?
|
Wounds and Injuries | 1 | 2019 | 2513 | 0.070 |
Why?
|
Pyridones | 1 | 1991 | 819 | 0.070 |
Why?
|
Placebos | 1 | 2010 | 1660 | 0.060 |
Why?
|
Data Mining | 1 | 2011 | 561 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2024 | 5886 | 0.060 |
Why?
|
Tunica Intima | 1 | 2008 | 455 | 0.060 |
Why?
|
Treatment Outcome | 3 | 2024 | 65295 | 0.060 |
Why?
|
Injections, Intravenous | 1 | 2008 | 1377 | 0.060 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2009 | 453 | 0.060 |
Why?
|
Incidence | 2 | 2017 | 21526 | 0.060 |
Why?
|
Advisory Committees | 2 | 2006 | 797 | 0.060 |
Why?
|
Quality Indicators, Health Care | 1 | 2014 | 1804 | 0.060 |
Why?
|
Alphapapillomavirus | 1 | 2007 | 219 | 0.060 |
Why?
|
Decision Making | 1 | 2018 | 3951 | 0.060 |
Why?
|
Cross-Over Studies | 1 | 2010 | 2105 | 0.060 |
Why?
|
Coronary Thrombosis | 1 | 2007 | 440 | 0.060 |
Why?
|
Death | 1 | 2008 | 685 | 0.060 |
Why?
|
Prevalence | 1 | 2021 | 15851 | 0.050 |
Why?
|
Speech | 1 | 2008 | 555 | 0.050 |
Why?
|
Anticoagulants | 1 | 2019 | 4854 | 0.050 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2007 | 12250 | 0.050 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 1992 | 1337 | 0.050 |
Why?
|
Angina Pectoris | 2 | 1984 | 956 | 0.050 |
Why?
|
Aneuploidy | 1 | 2006 | 573 | 0.050 |
Why?
|
Pacemaker, Artificial | 1 | 2008 | 828 | 0.050 |
Why?
|
Information Services | 1 | 2003 | 239 | 0.050 |
Why?
|
Knowledge | 1 | 2023 | 178 | 0.050 |
Why?
|
Confidence Intervals | 1 | 2007 | 2920 | 0.050 |
Why?
|
Pregnancy | 1 | 2023 | 30238 | 0.050 |
Why?
|
Glucocorticoids | 1 | 2010 | 2163 | 0.050 |
Why?
|
Papillomavirus Vaccines | 1 | 2007 | 497 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2021 | 26396 | 0.040 |
Why?
|
DNA, Neoplasm | 1 | 2006 | 1741 | 0.040 |
Why?
|
Aged | 13 | 2022 | 171319 | 0.040 |
Why?
|
Science | 1 | 2003 | 234 | 0.040 |
Why?
|
Triglycerides | 1 | 2008 | 2444 | 0.040 |
Why?
|
Terrorism | 1 | 2003 | 211 | 0.040 |
Why?
|
Disease Outbreaks | 1 | 2009 | 1761 | 0.040 |
Why?
|
Neoplasms | 1 | 2008 | 22350 | 0.040 |
Why?
|
Thromboembolism | 1 | 2006 | 1003 | 0.040 |
Why?
|
Adult | 10 | 2020 | 223317 | 0.040 |
Why?
|
Quality of Life | 1 | 2020 | 13485 | 0.040 |
Why?
|
Societies, Medical | 1 | 2011 | 3964 | 0.040 |
Why?
|
Weight Loss | 1 | 2010 | 2716 | 0.040 |
Why?
|
Population Surveillance | 1 | 2009 | 2594 | 0.040 |
Why?
|
Hospitalization | 1 | 2018 | 10815 | 0.040 |
Why?
|
Sports Equipment | 1 | 1998 | 27 | 0.040 |
Why?
|
Research Design | 2 | 2006 | 6210 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7871 | 0.040 |
Why?
|
Coma | 1 | 2002 | 485 | 0.040 |
Why?
|
Protective Devices | 1 | 1998 | 72 | 0.040 |
Why?
|
Syndrome | 1 | 2024 | 3271 | 0.040 |
Why?
|
Energy Metabolism | 2 | 2003 | 2906 | 0.040 |
Why?
|
Influenza, Human | 1 | 2009 | 1543 | 0.040 |
Why?
|
Exercise Tolerance | 1 | 2003 | 846 | 0.040 |
Why?
|
Consumer Product Safety | 1 | 1998 | 122 | 0.040 |
Why?
|
Research | 2 | 2003 | 1977 | 0.040 |
Why?
|
Cations, Monovalent | 1 | 1977 | 24 | 0.040 |
Why?
|
Cardiac Glycosides | 1 | 1977 | 29 | 0.040 |
Why?
|
Baseball | 1 | 1998 | 95 | 0.040 |
Why?
|
Male | 22 | 2019 | 364203 | 0.030 |
Why?
|
Myocardial Contraction | 4 | 1991 | 1516 | 0.030 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2018 | 348 | 0.030 |
Why?
|
Drug Delivery Systems | 1 | 2007 | 2212 | 0.030 |
Why?
|
Cohort Studies | 1 | 2018 | 41718 | 0.030 |
Why?
|
Resuscitation Orders | 1 | 2017 | 271 | 0.030 |
Why?
|
Papillomavirus Infections | 1 | 2007 | 1639 | 0.030 |
Why?
|
Interinstitutional Relations | 1 | 2016 | 235 | 0.030 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2007 | 2764 | 0.030 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2007 | 2038 | 0.030 |
Why?
|
Length of Stay | 2 | 1988 | 6489 | 0.030 |
Why?
|
Cell Division | 1 | 2002 | 4473 | 0.030 |
Why?
|
Survival Rate | 1 | 2008 | 12823 | 0.030 |
Why?
|
Thyroid Hormones | 1 | 1977 | 408 | 0.030 |
Why?
|
Fasting | 1 | 1980 | 1607 | 0.030 |
Why?
|
Isosorbide Dinitrate | 2 | 1984 | 34 | 0.030 |
Why?
|
Prognosis | 2 | 2006 | 29963 | 0.030 |
Why?
|
Infusions, Parenteral | 2 | 1984 | 395 | 0.030 |
Why?
|
Adenosine Triphosphatases | 1 | 1977 | 840 | 0.030 |
Why?
|
Myocardial Ischemia | 1 | 2003 | 2131 | 0.020 |
Why?
|
Stem Cells | 2 | 2002 | 3535 | 0.020 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 1992 | 286 | 0.020 |
Why?
|
Milrinone | 1 | 1991 | 86 | 0.020 |
Why?
|
Organizational Innovation | 1 | 2014 | 539 | 0.020 |
Why?
|
Drug Combinations | 1 | 1997 | 2086 | 0.020 |
Why?
|
Political Systems | 1 | 1990 | 23 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2016 | 1512 | 0.020 |
Why?
|
Proteins | 2 | 1981 | 6001 | 0.020 |
Why?
|
Forecasting | 1 | 2017 | 2936 | 0.020 |
Why?
|
Physical Fitness | 1 | 1993 | 744 | 0.020 |
Why?
|
Oxygen Consumption | 3 | 1986 | 1873 | 0.020 |
Why?
|
Tyrosine | 3 | 1981 | 1425 | 0.020 |
Why?
|
Swine | 1 | 1998 | 5987 | 0.020 |
Why?
|
Early Ambulation | 1 | 1988 | 49 | 0.020 |
Why?
|
Time Factors | 3 | 2008 | 40154 | 0.020 |
Why?
|
Tachycardia | 1 | 1990 | 598 | 0.020 |
Why?
|
Clinical Competence | 1 | 2023 | 4859 | 0.020 |
Why?
|
Aging | 1 | 1986 | 8729 | 0.020 |
Why?
|
Cycloheximide | 3 | 1981 | 340 | 0.020 |
Why?
|
Infant | 1 | 2008 | 36485 | 0.020 |
Why?
|
Cardiac Output | 2 | 1986 | 837 | 0.020 |
Why?
|
Cardiac Pacing, Artificial | 1 | 1990 | 881 | 0.020 |
Why?
|
Anti-Arrhythmia Agents | 1 | 1990 | 773 | 0.020 |
Why?
|
Leadership | 1 | 2014 | 1394 | 0.020 |
Why?
|
Middle Aged | 13 | 2019 | 223233 | 0.010 |
Why?
|
Heart Atria | 2 | 1981 | 1362 | 0.010 |
Why?
|
Dobutamine | 1 | 1984 | 114 | 0.010 |
Why?
|
Pulmonary Gas Exchange | 1 | 1986 | 389 | 0.010 |
Why?
|
Ointments | 1 | 1984 | 58 | 0.010 |
Why?
|
Catecholamines | 1 | 1984 | 388 | 0.010 |
Why?
|
Random Allocation | 1 | 1988 | 2394 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2017 | 5345 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2002 | 7469 | 0.010 |
Why?
|
Aortic Valve Insufficiency | 2 | 1979 | 575 | 0.010 |
Why?
|
Reimbursement Mechanisms | 1 | 2008 | 670 | 0.010 |
Why?
|
Systems Analysis | 1 | 2002 | 168 | 0.010 |
Why?
|
Organogenesis | 1 | 2002 | 214 | 0.010 |
Why?
|
Life Style | 1 | 1993 | 3931 | 0.010 |
Why?
|
Organizational Policy | 1 | 2002 | 435 | 0.010 |
Why?
|
Adenosine Monophosphate | 1 | 1981 | 232 | 0.010 |
Why?
|
Captopril | 1 | 1980 | 261 | 0.010 |
Why?
|
Child | 1 | 2007 | 80771 | 0.010 |
Why?
|
Exercise Therapy | 1 | 1986 | 939 | 0.010 |
Why?
|
Leucine | 1 | 1980 | 547 | 0.010 |
Why?
|
Proline | 1 | 1980 | 454 | 0.010 |
Why?
|
Pharmacogenetics | 1 | 2002 | 682 | 0.010 |
Why?
|
Heart Valves | 1 | 1979 | 284 | 0.010 |
Why?
|
Risk Assessment | 2 | 2013 | 24299 | 0.010 |
Why?
|
Heart Septum | 1 | 1979 | 304 | 0.010 |
Why?
|
Rubidium | 1 | 1977 | 120 | 0.010 |
Why?
|
Adenosine Triphosphate | 2 | 1981 | 2001 | 0.010 |
Why?
|
Blood Vessels | 1 | 2002 | 1110 | 0.010 |
Why?
|
Biological Transport, Active | 1 | 1977 | 323 | 0.010 |
Why?
|
Aminopyridines | 1 | 1980 | 578 | 0.010 |
Why?
|
Muscle Proteins | 1 | 1981 | 1160 | 0.010 |
Why?
|
Case-Control Studies | 1 | 1993 | 22254 | 0.010 |
Why?
|
Guinea Pigs | 1 | 1977 | 1309 | 0.010 |
Why?
|
Triiodothyronine | 1 | 1977 | 493 | 0.010 |
Why?
|
Prospective Studies | 3 | 1991 | 54886 | 0.010 |
Why?
|
Cardiovascular System | 1 | 2002 | 839 | 0.010 |
Why?
|
Pericardial Effusion | 1 | 1976 | 246 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2013 | 6573 | 0.010 |
Why?
|
Animals | 5 | 1998 | 168965 | 0.010 |
Why?
|
Coronary Vessels | 1 | 1984 | 3114 | 0.010 |
Why?
|
Adolescent | 5 | 2018 | 89046 | 0.010 |
Why?
|
Radionuclide Imaging | 3 | 1984 | 1987 | 0.010 |
Why?
|
Tissue Engineering | 1 | 2002 | 1861 | 0.010 |
Why?
|
Potassium | 1 | 1977 | 1314 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 59980 | 0.010 |
Why?
|
Muscles | 1 | 1977 | 1576 | 0.010 |
Why?
|
Sodium | 1 | 1977 | 1594 | 0.010 |
Why?
|
Heart Valve Prosthesis | 2 | 1979 | 1464 | 0.010 |
Why?
|
Computational Biology | 1 | 2002 | 3567 | 0.010 |
Why?
|
Refractory Period, Electrophysiological | 1 | 1990 | 40 | 0.010 |
Why?
|
Rats | 3 | 1981 | 23713 | 0.010 |
Why?
|
Proteomics | 1 | 2002 | 3913 | 0.000 |
Why?
|
Glucose | 1 | 1980 | 4341 | 0.000 |
Why?
|
Lung | 1 | 1986 | 10076 | 0.000 |
Why?
|
Mutation | 1 | 1992 | 30211 | 0.000 |
Why?
|
Genetic Variation | 1 | 2002 | 6611 | 0.000 |
Why?
|
Echocardiography | 2 | 1979 | 5042 | 0.000 |
Why?
|
Genomics | 1 | 2002 | 5924 | 0.000 |
Why?
|
Insulin | 1 | 1980 | 6602 | 0.000 |
Why?
|
Rest | 1 | 1990 | 941 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 2008 | 20741 | 0.000 |
Why?
|
Lung Neoplasms | 1 | 2008 | 13491 | 0.000 |
Why?
|
Cardiac Surgical Procedures | 1 | 1979 | 3683 | 0.000 |
Why?
|
Stroke Volume | 2 | 1990 | 5618 | 0.000 |
Why?
|
Computers | 1 | 1984 | 589 | 0.000 |
Why?
|
Methoxamine | 1 | 1981 | 45 | 0.000 |
Why?
|
Phentolamine | 1 | 1981 | 102 | 0.000 |
Why?
|
Isoproterenol | 1 | 1981 | 398 | 0.000 |
Why?
|
Liver | 1 | 1977 | 7578 | 0.000 |
Why?
|
Phosphocreatine | 1 | 1981 | 259 | 0.000 |
Why?
|
Amrinone | 1 | 1980 | 14 | 0.000 |
Why?
|
Rats, Inbred Strains | 1 | 1981 | 2078 | 0.000 |
Why?
|
Blood Urea Nitrogen | 1 | 1980 | 189 | 0.000 |
Why?
|
Propranolol | 1 | 1981 | 493 | 0.000 |
Why?
|
Hemodynamics | 2 | 1980 | 4186 | 0.000 |
Why?
|
Marfan Syndrome | 1 | 1979 | 237 | 0.000 |
Why?
|
Cyclic AMP | 1 | 1981 | 1472 | 0.000 |
Why?
|
Angiotensin II | 1 | 1980 | 842 | 0.000 |
Why?
|
Vascular Resistance | 1 | 1980 | 939 | 0.000 |
Why?
|
Amino Acids | 1 | 1981 | 1712 | 0.000 |
Why?
|
Long-Term Care | 1 | 1979 | 631 | 0.000 |
Why?
|
Endocarditis | 1 | 1979 | 352 | 0.000 |
Why?
|
Cardiac Tamponade | 1 | 1976 | 175 | 0.000 |
Why?
|
Creatinine | 1 | 1980 | 1916 | 0.000 |
Why?
|
Protein Kinases | 1 | 1981 | 1610 | 0.000 |
Why?
|
Kinetics | 1 | 1981 | 6287 | 0.000 |
Why?
|
Movement | 1 | 1979 | 1473 | 0.000 |
Why?
|
Glomerular Filtration Rate | 1 | 1980 | 2227 | 0.000 |
Why?
|
Coronary Artery Bypass | 1 | 1979 | 2189 | 0.000 |
Why?
|
Heart Ventricles | 1 | 1980 | 3837 | 0.000 |
Why?
|
Mitral Valve Insufficiency | 1 | 1976 | 1414 | 0.000 |
Why?
|
Radiography | 1 | 1976 | 6975 | 0.000 |
Why?
|
Follow-Up Studies | 1 | 1979 | 39317 | 0.000 |
Why?
|
Postoperative Complications | 1 | 1979 | 15824 | 0.000 |
Why?
|
Retrospective Studies | 1 | 1976 | 81659 | 0.000 |
Why?
|